BROWSE

Related Scientist

Byung Gyu, Kim's photo.

Byung Gyu, Kim
유전체 항상성 연구단
more info

ITEM VIEW & DOWNLOAD

PDK2 Deficiency Prevents Ovariectomy-Induced Bone Loss in Mice by Regulating the RANKL-NFATc1 Pathway During Osteoclastogenesis

Cited 0 time in webofscience Cited 0 time in scopus
13 Viewed 0 Downloaded
Title
PDK2 Deficiency Prevents Ovariectomy-Induced Bone Loss in Mice by Regulating the RANKL-NFATc1 Pathway During Osteoclastogenesis
Author(s)
Lee, J.-M.; Kim, M.-J.; Lee, S.J.; Byung Gyu, Kim; Choi, J.-Y.; Lee, S.M.; Ham, H.J.; Jung-Min Koh; Jeon, J.-H.; Lee, I.-K.
Publication Date
2021-03
Journal
JOURNAL OF BONE AND MINERAL RESEARCH, v.36, no.3, pp.553 - 566
Publisher
WILEY
Abstract
Estrogen deficiency leads to osteoporosis as a result of an imbalance in bone remodeling due to greater bone resorption. Estrogen deficiency increases the osteoclastic resorption of bone, and many of the FDA-approved therapies for osteoporosis are antiresorptive drugs that mainly act by reducing osteoclast activity. The mitochondrial enzyme pyruvate dehydrogenase kinase (PDK) is a critical regulator of aerobic glycolysis that exerts its effects by phosphorylating the pyruvate dehydrogenase complex (PDC), which is responsible for oxidative phosphorylation. In the present study, we found that during osteoclast differentiation, PDK2 expression increased more than that of the other PDK isoenzymes. Bone loss was delayed and the number of osteoclasts was lower in ovariectomized (OVX) Pdk2(-/-) mice than in OVX wild-type mice. The differentiation of osteoclasts was suppressed in Pdk2(-/-) bone marrow-derived monocyte/macrophage lineage cells, which was associated with lower phosphorylation of cAMP response element-binding protein (CREB) and c-FOS, and a consequent reduction in NFATc1 transcription. Administration of AZD7545, a specific inhibitor of PDK2, prevented the OVX-induced bone loss and reduced the phosphorylation of CREB and c-FOS, and the protein expression of NFATc1, in osteoclasts. Collectively, these results indicate that the inhibition of PDK2 prevents osteoporosis in estrogen-deficient mice by reducing aberrant osteoclast activation, probably via inhibition of the RANKL-CREB-cFOS-NFATc1 pathway. These findings imply that PDK2 inhibitors might be repurposed for the therapy of estrogen deficiency-induced osteoporosis. (c) 2020 American Society for Bone and Mineral Research (ASBMR).
URI
https://pr.ibs.re.kr/handle/8788114/10068
DOI
10.1002/jbmr.4202
ISSN
0884-0431
Appears in Collections:
Center for Genomic Integrity(유전체 항상성 연구단) > 1. Journal Papers (저널논문)
Files in This Item:
There are no files associated with this item.

qrcode

  • facebook

    twitter

  • Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
해당 아이템을 이메일로 공유하기 원하시면 인증을 거치시기 바랍니다.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse